Pfizer kicks newly acquired meds out of Arena as part of midstage cleaning

Pfizer has taken the broom to three midstage medicines from the acquisition of Arena Pharmaceuticals, deciding that etrasimod alone was worthy of the biotech’s $6.7 billion price tag.